Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
The Food and Drug Administration has approved a new type of breast cancer drug developed by ImmunoGen (NASDAQ: IMGN ) and Roche (NASDAQOTH: RHHBY ) , and will be marketed by the latter. The medication, known by the brand name Kadcyla, is used to treat HER 2-positive metastatic breast cancer. It is a combination of Herceptin, an existing Roche drug, with a pair of components developed by ImmunoGen.
HER2 is a protein found on the tumors of roughly 20% to 25% of patients with breast cancer.
The approval will trigger a $10.5 million payment from Roche to ImmunoGen. The latter will also be paid royalties of up to 5% on sales of Kadcyla, which will cost $9,800 per month.